Benefits
Stomach ulcer healing and mucosal protection
As the medicine polaprezinc, zinc-L-carnosine has been used in Japan since the 1990s to help heal gastric ulcers. It thickens the protective mucus layer, supports repair of the stomach lining, and reduces acid-related damage.
Gut-lining and leaky-gut support
By adhering to the gut wall and delivering zinc locally, zinc-L-carnosine helps strengthen the intestinal barrier. In a small human study it prevented the roughly three-fold rise in gut permeability caused by an NSAID.
Support alongside H. pylori treatment
Added to standard antibiotic therapy for Helicobacter pylori, zinc-L-carnosine improved treatment-related outcomes in a randomized trial, likely by protecting the stomach lining and easing inflammation. It is an adjunct, not a standalone treatment.
Protection against NSAID-related gut injury
In a small controlled study, zinc-L-carnosine reduced small-bowel damage from low-dose aspirin, fitting its role as a protector of the gut lining against common irritants.
Mechanism of action
Sticks to the gut lining for local action
The chelate has a high affinity for the mucous glycoproteins that coat the stomach and intestine, so it adheres to damaged tissue and releases zinc and carnosine locally instead of being quickly absorbed and cleared.
Zinc supports tissue repair
Locally released zinc promotes proliferation of the cells that line the gut and supports assembly of tight-junction proteins, helping rebuild a healthy barrier.
Carnosine calms oxidative and inflammatory stress
L-carnosine scavenges reactive oxygen species, binds metal ions that catalyze damage, and dampens NF-kB inflammatory signaling, complementing zinc's structural repair.
Clinical trials
Multicenter, randomised, double-blind, double-dummy, positive-controlled trial of polaprezinc (zinc-L-carnosine) for gastric ulcer healing (Shen W, Zhao X, Han Z, Miao Y, Huang H, Zhang Z, Dong L, Nie Y, Li H, Ni R 2022, Med Eng Phys 110:103860, PMID 35999163).
Adults with gastric ulcer, across multiple centers.
Polaprezinc supported gastric ulcer healing and was comparable (non-inferior) to the active comparator drug, reflecting its established role as an anti-ulcer medicine. This gastric indication is the compound's strongest evidence.
Combined human and experimental study of oral zinc carnosine on gut integrity and repair (Mahmood A, FitzGerald AJ, Marchbank T, Ntatsaki E, Murray D, Ghosh S, Playford RJ 2007, Gut 56(2):168-175, PMID 16777920).
Healthy volunteers (small human component) plus cell and animal models.
Oral zinc carnosine stabilized the gut lining and prevented the roughly three-fold increase in intestinal permeability caused by the NSAID indomethacin, and stimulated gut repair in laboratory models. Small human component; this is the foundation for the leaky-gut supplement use.
Prospective, multicenter, randomised trial of polaprezinc added to clarithromycin-based triple therapy for H. pylori-associated gastritis (Tan B, Luo HQ, Xu H, Lv NH, Shi RH, Luo HS, et al. 2017, PLoS One 12(4):e0175625, PMID 28407007).
Adults with Helicobacter pylori-associated gastritis.
Adding polaprezinc to standard antibiotic therapy improved eradication-related outcomes versus therapy alone, supporting its use as an adjunct to, not a replacement for, H. pylori treatment.